Stock listing
NASDAQ:PRFX PRF Technologies Ltd. Stock
Home listing (NASDAQ) of PRF Technologies Ltd.
Follow PRF Technologies Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:PRFX
$0.476 USD -0.148 (-23.7%)
Close on Nov 20, 2026
- Day range
- $0.460 – $0.601 USDNov 20, 2026
- Volume
- 69,891 sharesNov 20, 2026
- Market cap
- $1.66M USDAt the close on Nov 20, 2026 · price × 3.50M shares outstanding
- 52-week range
- $0.460 – $7.950 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $199,310 USDMedian day 48,728 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PRFX · Home | $0.476 USD | -0.148 (-23.7%) | 69,891 | $0.601 | $0.601 | $0.460 | $0.623 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PRFX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.476 | -0.148 | -23.7% | $0.601 | $0.601 | $0.460 | 69,891 | |
| $0.623 | -0.025 | -3.8% | $0.640 | $0.640 | $0.608 | 28,618 | |
| $0.648 | -0.013 | -2.0% | $0.660 | $0.660 | $0.604 | 46,079 | |
| $0.661 | -0.034 | -4.9% | $0.700 | $0.700 | $0.660 | 21,562 | |
| $0.695 | -0.088 | -11.2% | $0.780 | $0.780 | $0.680 | 87,065 | |
| $0.783 | -0.004 | -0.5% | $0.738 | $0.866 | $0.697 | 352,609 | |
| $0.787 | +0.043 | +5.8% | $0.715 | $0.787 | $0.680 | 273,366 | |
| $0.744 | -0.053 | -6.7% | $0.820 | $0.820 | $0.671 | 28,909 | |
| $0.797 | -0.015 | -1.8% | $0.780 | $0.810 | $0.740 | 20,711 | |
| $0.811 | -0.060 | -6.8% | $0.827 | $0.887 | $0.769 | 48,940 | |
| $0.871 | +0.112 | +14.8% | $0.887 | $0.887 | $0.762 | 72,346 | |
| $0.759 | -0.006 | -0.8% | $0.778 | $0.800 | $0.740 | 97,086 | |
| $0.765 | +0.054 | +7.6% | $0.672 | $0.830 | $0.641 | 448,820 | |
| $0.711 | -0.039 | -5.2% | $0.770 | $0.777 | $0.710 | 3,787,191 | |
| $0.750 | +0.020 | +2.7% | $0.792 | $0.830 | $0.750 | 22,777 | |
| $0.730 | -0.020 | -2.7% | $0.732 | $0.742 | $0.710 | 58,595 | |
| $0.750 | -0.030 | -3.9% | $0.780 | $0.780 | $0.725 | 30,041 | |
| $0.780 | +0.022 | +2.8% | $0.760 | $0.824 | $0.759 | 6,359 | |
| $0.759 | +0.019 | +2.6% | $0.721 | $0.776 | $0.721 | 34,386 | |
| $0.739 | -0.001 | -0.1% | $0.740 | $0.760 | $0.720 | 17,878 | |
| $0.740 | +0.020 | +2.8% | $0.716 | $0.740 | $0.698 | 54,731 | |
| $0.720 | -0.044 | -5.7% | $0.752 | $0.752 | $0.700 | 37,615 | |
| $0.764 | +0.039 | +5.4% | $0.755 | $0.784 | $0.753 | 18,106 | |
| $0.725 | +0.013 | +1.8% | $0.750 | $0.785 | $0.725 | 15,643 | |
| $0.712 | -0.069 | -8.9% | $0.798 | $0.804 | $0.691 | 81,930 | |
| $0.781 | -0.065 | -7.6% | $0.812 | $0.833 | $0.781 | 7,605 | |
| $0.846 | +0.027 | +3.3% | $0.817 | $0.865 | $0.810 | 36,404 | |
| $0.819 | +0.001 | +0.1% | $0.835 | $0.840 | $0.810 | 55,385 | |
| $0.818 | -0.042 | -4.9% | $0.858 | $0.867 | $0.812 | 44,041 | |
| $0.860 | -0.019 | -2.2% | $0.910 | $0.915 | $0.855 | 25,607 | |
| $0.879 | +0.020 | +2.4% | $0.880 | $0.889 | $0.855 | 31,839 | |
| $0.859 | -0.019 | -2.2% | $0.886 | $0.894 | $0.851 | 20,497 | |
| $0.878 | -0.002 | -0.3% | $0.882 | $0.895 | $0.878 | 17,702 | |
| $0.880 | -0.004 | -0.5% | $0.895 | $0.925 | $0.880 | 35,763 | |
| $0.884 | -0.036 | -3.9% | $0.920 | $0.929 | $0.872 | 68,902 | |
| $0.920 | -0.030 | -3.2% | $0.920 | $0.939 | $0.910 | 51,893 | |
| $0.950 | 0.000 | 0.0% | $0.966 | $0.966 | $0.950 | 22,957 | |
| $0.950 | +0.005 | +0.6% | $0.967 | $0.978 | $0.950 | 10,273 | |
| $0.945 | -0.027 | -2.7% | $0.965 | $0.970 | $0.945 | 11,829 | |
| $0.972 | -0.005 | -0.5% | $0.990 | $1.020 | $0.960 | 41,468 | |
| $0.977 | -0.005 | -0.5% | $0.989 | $1.019 | $0.950 | 43,478 | |
| $0.982 | -0.018 | -1.8% | $1.000 | $1.010 | $0.971 | 106,436 | |
| $1.000 | +0.070 | +7.5% | $0.955 | $1.090 | $0.955 | 164,331 | |
| $0.931 | -0.031 | -3.2% | $0.977 | $0.993 | $0.901 | 61,938 | |
| $0.962 | -0.058 | -5.7% | $1.020 | $1.080 | $0.950 | 127,345 | |
| $1.020 | 0.000 | 0.0% | $1.050 | $1.060 | $1.005 | 96,002 | |
| $1.020 | +0.010 | +1.0% | $1.000 | $1.140 | $0.971 | 276,133 | |
| $1.010 | +0.110 | +12.2% | $0.911 | $1.270 | $0.911 | 6,087,349 | |
| $0.900 | +0.039 | +4.6% | $0.860 | $0.919 | $0.855 | 79,478 | |
| $0.861 | +0.000 | 0.0% | $0.909 | $0.909 | $0.855 | 23,811 | |
| $0.860 | -0.067 | -7.3% | $0.912 | $0.930 | $0.852 | 88,810 | |
| $0.928 | -0.023 | -2.4% | $0.961 | $0.961 | $0.921 | 51,380 | |
| $0.950 | +0.005 | +0.6% | $0.983 | $0.983 | $0.935 | 36,714 | |
| $0.945 | -0.023 | -2.4% | $0.990 | $0.990 | $0.930 | 26,621 | |
| $0.968 | -0.011 | -1.1% | $0.999 | $1.000 | $0.927 | 51,281 | |
| $0.979 | +0.005 | +0.5% | $0.952 | $1.010 | $0.921 | 724,827 | |
| $0.975 | +0.023 | +2.4% | $0.936 | $0.979 | $0.936 | 26,495 | |
| $0.951 | -0.002 | -0.3% | $0.955 | $0.962 | $0.940 | 21,258 | |
| $0.954 | -0.007 | -0.8% | $0.960 | $0.995 | $0.940 | 49,341 | |
| $0.961 | -0.026 | -2.6% | $0.990 | $1.015 | $0.942 | 41,970 | |
| $0.987 | +0.010 | +1.0% | $0.990 | $1.020 | $0.986 | 85,489 | |
| $0.977 | -0.018 | -1.8% | $0.995 | $0.995 | $0.950 | 64,803 | |
| $0.995 | -0.015 | -1.5% | $1.030 | $1.050 | $0.980 | 48,515 | |
| $1.010 | +0.013 | +1.3% | $0.979 | $1.010 | $0.960 | 49,502 | |
| $0.997 | -0.003 | -0.3% | $1.000 | $1.050 | $0.980 | 67,994 | |
| $1.000 | -0.010 | -1.0% | $0.984 | $1.010 | $0.971 | 53,221 |
Splits
3 splits since 2023 · NASDAQ:PRFX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation | |
| 1-for-6 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:PRFX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
PRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a Hearing
Latest news
PRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a Hearing
Nov 12, 2026
Closed $0.783 (-0.5%) on Nov 13, 2026
PRF Technologies and Dotz Nano Sign Term Sheet for Strategic Collaboration to Expand AI-Driven Energy Optimization Offering
Nov 3, 2026
Closed $0.765 (+7.6%) on Nov 4, 2026
PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power
Oct 23, 2026
Closed $0.74 (+2.8%) on Oct 23, 2026
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform
Sep 9, 2026
Closed $0.95 (+0.6%) on Sep 9, 2026
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business
Sep 3, 2026
Closed $0.979 (+0.5%) on Sep 3, 2026
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
Jul 27, 2026
Closed $1.09 (-4.0%) on Jul 27, 2026
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
Jul 21, 2026
Closed $1.20 (+4.3%) on Jul 21, 2026
PRF Technologies Expands DeepSolar Predict Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
Jul 16, 2026
Closed $1.18 (-7.1%) on Jul 16, 2026
PRF Technologies’ DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
Jul 8, 2026
Closed $1.27 (-5.2%) on Jul 8, 2026
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Jun 25, 2026
Closed $1.60 (+13.5%) on Jun 25, 2026
PRF Technologies Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 86 in all · newest Nov 12, 2026 · oldest 2020
- Decks
- 9 decks · latest April 2023
Where PRF Technologies Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PRFX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PRFX | BOATS | United States | USD |
Valuation
EV/sales −249× against a median of 16.9×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$9.82M USD
- P/E
- Loss
- EV/sales
- −249×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- −307.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.93
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Genprex, Inc. · NASDAQ:GNPX | US$1.94M | −US$13.41M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.08 |
| Propanc Biopharma, Inc. · NASDAQ:PPCB | US$1.84M | US$1.62M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.39 |
| Argent Biopharma Ltd · ASX:RGT | US$1.79M | US$8.05M | n/a | 75.4× | n/a | n/a | n/a | n/a | n/a |
| Calidi Biotherapeutics, Inc. · AMEX:CLDI | US$1.76M | −US$2.19M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.86 |
| Kala Bio, Inc. · NASDAQ:KALA | US$1.74M | −US$5.49M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 2.76 |
| SOHM, Inc. · OTC:SHMN | US$1.74M | US$4.99M | n/a | 5.5× | n/a | 0.5× | −28.1% | 0.9× | -0.10 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Kairos Pharma, Ltd. · AMEX:KAPA | US$1.48M | −US$1.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.36 |
| BioRestorative Therapies, Inc. · NASDAQ:BRTX | US$1.45M | −US$2.11M | n/a | −5.9× | n/a | 0.5× | n/a | 0.0× | 1.81 |
| Nutra Pharma Corp. · OTC:NPHC | US$1.43M | US$13.99M | n/a | 87.0× | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$1.74M | −US$160,781 | 16.9× | 0.4× | −28.1% | 0.0× | 1.60 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.00 USD · Analysts' mean
Team and board
Officers
| Officer | Role |
|---|---|
| Ehud Geller | Executive Chairman & Interim CEO |
| Eyal Broder | Interim CFO |
| Sigal Aviel | COO |
| Rita Keynan | Vice President of Pharmaceutical Operations |
Board
| Director | Role |
|---|---|
| Ehud Geller | Executive Chairman & Interim CEO |
| Asi Shavit | Director |
| Augustine Lawlor | Director |
| Efi Cohen-Arazi | Director |
| Ellen Baron | Director |
| Gus Lawlor | Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Nov 27, 2025 | +4.3% |
| Q2 2025 | Aug 29, 2025 | −6.1% |
| Q1 2025 | Apr 7, 2025 | −16.3% |
| Quarter to Dec 31, 2024 | Mar 31, 2025 | +3.2% |
| Q3 2024 | Nov 12, 2024 | +3.2% |
| Q2 2024 | Aug 15, 2024 · After close | +11.3% |
| Q1 2024 | May 15, 2024 · After close | 0.0% |
| Q4 2023 | Feb 29, 2024 · After close | +21.4% |
| Q3 2023 | Nov 15, 2023 · After close | −4.7% |
| Q2 2023 | Aug 10, 2023 · After close | −0.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 16, 2023 · Before open | +3.7% |
| Q4 2022 | Mar 15, 2023 · After close | −0.9% |
| Q3 2022 | Nov 14, 2022 · After close | −3.5% |
| Q2 2022 | Aug 15, 2022 · After close | +0.1% |
| Q1 2022 | May 16, 2022 · After close | +12.8% |
| Q4 2021 | Mar 17, 2022 · Before open | −14.2% |
| Q3 2021 | Nov 15, 2021 · After close | −9.4% |
| Q2 2021 | Aug 16, 2021 · Before open | −5.6% |
| Quarter to Mar 31, 2021 | May 13, 2021 · Before open | +5.6% |
| Quarter to Dec 31, 2020 | Mar 18, 2021 · After close | −8.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| PainReform — Investor Presentation (April 2023) | Investor deck | 19 slides | April 2023 |
| PainReform — Investor Presentation (July 2022) | Investor deck | 19 slides | Jul 29, 2022 |
| PainReform — Investor Presentation (July 2022) | Investor deck | 19 slides | July 2022 |
| PainReform — Investor Presentation (April 2022) | Investor deck | 19 slides | April 2022 |
| PainReform — Investor Presentation (July 2021) | Investor deck | 16 slides | July 2021 |
| PainReform — Investor Presentation (January 2021) | Investor deck | 16 slides | Jan 5, 2021 |
| PainReform — Investor Presentation (January 2021) | Investor deck | 16 slides | January 2021 |
| PainReform — Investor Presentation (October 2020) | Investor deck | 19 slides | October 2020 |
| PainReform — IPO Roadshow (August 2020) | IPO roadshow | 19 slides | August 2020 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of ordinary shares Closed: US$900,000 raised | Apr 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as PAINREFORM LTD. Priced at US$7.99 a share on Sep 1, 2020.
- Price
- US$7.99 a share
- Units offered
- 2,500,000 units
- Underwriters' option
- Up to 375,000 more units
- Listing
- PRFX on the Nasdaq Capital Market
- Underwriters
- Maxim Group LLC, Joseph Gunnar & Co., LLC · In the order on the cover
- Units delivered
- On or about Sep 3, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 3, 2020 |
| Filed publicly | Jun 30, 2020 |
| Amended 4 times | Newest Aug 31, 2020 |
| Shares registered with an exchange | Aug 31, 2020 |
| Declared effective by the SEC | Aug 31, 2020 |
| Final prospectus, with the price | Sep 2, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 2, 2020 |
| EFFECT · Notice that a registration is effective | Aug 31, 2020 |
| CERT · Exchange's certificate of listing | Aug 31, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 31, 2020 |
| F-1/A · Registration statement, amended | Aug 31, 2020 |
| CORRESP · Letter to the SEC | Aug 27, 2020 |
| CORRESP · Letter to the SEC | Aug 27, 2020 |
| F-1/A · Registration statement, amended | Aug 24, 2020 |
| CORRESP · Letter to the SEC | Aug 10, 2020 |
| F-1/A · Registration statement, amended | Aug 10, 2020 |
All 25 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Aug 10, 2020 |
| CORRESP · Letter to the SEC | Aug 5, 2020 |
| F-1/A · Registration statement, amended | Aug 5, 2020 |
| UPLOAD · Letter from the SEC | Jul 9, 2020 |
| CORRESP · Letter to the SEC | Jun 30, 2020 |
| F-1 · Registration statement | Jun 30, 2020 |
| UPLOAD · Letter from the SEC | Jun 16, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jun 2, 2020 |
| DRS/A · Draft registration statement, amended | Jun 2, 2020 |
| UPLOAD · Letter from the SEC | May 22, 2020 |
| DRSLTR · Letter to the SEC with a draft | May 12, 2020 |
| DRS/A · Draft registration statement, amended | May 12, 2020 |
| UPLOAD · Letter from the SEC | Feb 28, 2020 |
| DRSLTR · Letter to the SEC with a draft | Feb 3, 2020 |
| DRS · Draft registration statement | Feb 3, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 2, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.0K | 0 | 0 | 86.0K | 0 | 0 | 0 | 0 | |
| Cost of revenue | 70.0K | 0 | 0 | 15.0K | 7.00K | 1.00K | |||
| Gross profit | -827.0K | -16.0K | -15.0K | 71.0K | -7.00K | -1.00K | |||
| Research and development | 1.14M | 11.7M | 6.04M | 4.42M | 2.86M | 354.0K | 136.0K | 223.0K | 504.0K |
| Selling, general and administrative | 1.40M | 1.32M | 1.68M | 2.09M | 2.15M | 1.32M | 553.0K | 277.0K | 376.0K |
| Operating income | -5.12M | -14.7M | -9.58M | -8.87M | -7.21M | -1.67M | -689.0K | -500.0K | -880.0K |
| Depreciation and amortization | 15.0K | 16.0K | 15.0K | 15.0K | 7.00K | 1.00K | 1.00K | 500.0K | 880.0K |
| EBITDA | -5.11M | -14.7M | -9.57M | -8.85M | -7.20M | -1.67M | -688.0K | 0 | 0 |
| Interest expense | 10.0K | 14.0K | 384.0K | 61.0K | 10.0K | 271.0K | 379.0K | 324.0K | 0 |
| Income before tax | -5.01M | -14.6M | -9.34M | -8.78M | -7.24M | -3.83M | -1.28M | -828.0K | -1.12M |
| Income tax | 8.00K | 8.00K | 8.00K | 9.00K | 6.00K | 220.0K | 0 | 4.00K | -242.0K |
| Net income | -5.02M | -14.6M | -9.34M | -8.79M | -7.25M | -4.05M | -1.28M | -828.0K | -2.09M |
| Earnings per share, basic | -7.47 | -105.52 | -122.94 | -63.46 | -7.25 | -1.25 | -4.17 | -3.24 | -906.33 |
| Earnings per share, diluted | -7.47 | -105.52 | -122.94 | -63.46 | -7.25 | -1.25 | -4.17 | -3.24 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.13M | 4.26M | 8.03M | 4.10M | 16.5M | 15.7M | 941.0K | 46.0K | 187.0K |
| Short-term investments | 1.02M | 0 | 0 | 6.08M | 0 | ||||
| Receivables | 142.0K | 119.0K | 45.0K | 55.0K | 218.0K | 53.0K | 22.0K | 28.0K | 20.0K |
| Inventory | 7.82M | 2.23M | 2.04M | 6.00K | |||||
| Current assets | 4.35M | 4.43M | 9.80M | 12.3M | 19.0M | 17.8M | 972.0K | 80.0K | 213.0K |
| Property, plant and equipment | 30.0K | 35.0K | 38.0K | 44.0K | 53.0K | 10.0K | 1.00K | 1.00K | |
| Goodwill | 186.0K | 0 | |||||||
| Total assets | 12.0M | 4.53M | 9.93M | 12.3M | 19.1M | 17.8M | 1.16M | 81.0K | 214.0K |
| Accounts payable | 213.0K | 296.0K | 221.0K | 209.0K | 136.0K | 720.0K | 22.0K | 2.00K | 64.0K |
| Current liabilities | 2.44M | 2.44M | 2.41M | 1.06M | 757.0K | 961.0K | 6.34M | 18.0K | 135.0K |
| Long-term debt | 4.52M | ||||||||
| Total debt | 21.0K | 45.0K | 86.0K | 6.17M | 4.52M | 3.71M | |||
| Total liabilities | 2.71M | 2.70M | 2.69M | 1.31M | 991.0K | 1.18M | 6.79M | 4.54M | 3.84M |
| Shareholders' equity | 8.54M | 1.82M | 7.24M | 11.0M | 18.1M | 16.6M | -12.2M | -11.1M | -3.63M |
| Shares outstanding | 830.6K | 341.8K | 165.5K | 1.08M | 10.5M | 8.76M | 576.6K | 10.5M | 2.31K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.96M | -12.6M | -6.68M | -6.46M | -6.55M | -2.56M | -609.0K | -635.0K | -870.0K |
| Capital spending | -2.00K | -13.0K | -9.00K | -6.00K | -50.0K | -10.0K | 0 | -10.0K | -10.0K |
| Free cash flow | -3.96M | -12.6M | -6.69M | -6.46M | -6.60M | -2.57M | -609.0K | -635.0K | -870.0K |
| Cash from investing | -982.0K | -13.0K | 5.99M | -6.01M | -50.0K | -10.0K | 0 | -10.0K | -10.0K |
| Cash from financing | 3.82M | 8.86M | 4.62M | 0 | 7.48M | 17.3M | 1.51M | 488.0K | 699.0K |
| Change in cash | -1.12M | -3.77M | 3.93M | -12.5M | 881.0K | 14.7M | 901.0K | -147.0K | -171.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 19, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 3, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 23, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 28, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 24, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Sep 16, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 266 filings. Open Filings
Cap table
Built by 6ix from PRF Technologies Ltd.’s releases · as of Apr 7, 2025
- Common shares
- 3,499,144
- Fully diluted
- 3,499,144
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,499,144 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,499,144 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Augustine Lawlor Other companies: Cypherpunk Technologies Inc. (Chief Operating Officer · Since at least Jan 20, 2017); Gyre Therapeutics, Inc. (Director · Aug 20, 2015 – Aug 31, 2023 · Past); Globeimmune Inc (Director · Jul 1, 2014 – Mar 18, 2016 · Past); Cardiovascular Systems Inc (Director · Aug 31, 2012 – Apr 27, 2023 · Past); Human Genome Sciences Inc (Director · Oct 10, 2011 – Jul 30, 2012 · Past) | Director · Since at least Mar 18, 2026 |
| Efraim Cohen Arazi Other companies: Regentis Biomaterials Ltd. (Director · Since at least Mar 18, 2026) | Interim CEO, Director · Since at least Mar 18, 2026 |
| Ehud Geller Other companies: Regentis Biomaterials Ltd. (CEO & Chairman · Since at least Mar 18, 2026) | Executive Chairman & Interim CEO · Since at least Mar 18, 2026 |
| Asi Shavit | Director · Since at least Nov 5, 2026 |
| Efi Cohen Arazi | Director · Since at least Jul 21, 2026 |
| Ellen Baron | Director · Since at least Mar 18, 2026 |
| Eyal Broder | Interim CFO · Since at least Nov 5, 2026 |
| Gus Lawlor | Member · Since at least Nov 4, 2026 |
| Rita Keynan | Vice President of Pharmaceutical Operations · Since at least Nov 5, 2026 |
| Sigal Aviel | COO · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about PRF Technologies Ltd.